Bioinformation Therapy for Pancreatic Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

September 1, 2018

Study Completion Date

September 1, 2018

Conditions
Unresectable Pancreatic Cancer
Interventions
DEVICE

Cancer ablation

Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound

DRUG

Life information rehabilitation therapy

Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Trial Locations (1)

510665

Fuda cancer institute of Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shengxin Biotechnology Institute, Beijing

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT03239184 - Bioinformation Therapy for Pancreatic Cancer | Biotech Hunter | Biotech Hunter